Intraperitoneal chemotherapy of ovarian cancer

Women's Health

Volumn 3, Issue 4, 2007, Pages 433-440

  Lowe, Thomas ^a   Morgan, Robert J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Intraperitoneal chemotherapy; Ovarian cancer; Peritoneal catheter

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CIMETIDINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL;

ABDOMINAL PAIN; ADVANCED CANCER; AREA UNDER THE CURVE; BONE MARROW SUPPRESSION; CANCER MORTALITY; CANCER SURVIVAL; CATHETER REMOVAL; CAUSE OF DEATH; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TISSUE LEVEL; DYSPNEA; FATIGUE; GASTROINTESTINAL DISEASE; GRANULOCYTOPENIA; HEALTH CARE ORGANIZATION; HEALTH CARE QUALITY; HEARING LOSS; HEMATOLOGIC DISEASE; HUMAN; HYSTERECTOMY; LAPAROTOMY; LEUKOPENIA; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; OVARIECTOMY; OVARY CANCER; OVERALL SURVIVAL; PAIN; PATIENT COUNSELING; PERITONEAL CATHETER; PERITONEUM METASTASIS; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SECOND LOOK SURGERY; TINNITUS;

EID: 34447570620     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.3.4.433     Document Type: Review

References (40)

1. American Cancer Society: Cancer Facts and Figures 2007. American Cancer Society, Atlanta, GA, USA (2007).
2. Alberts DS, Liu PY, Hannigan EV et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N. Engl. J. Med. 335(26), 1950-1955 (1996).
3. Markman M, Bundy BN, Alberts DS et al.: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J. Clin. Oncol. 19(4), 1001-1007 (2001).
4. Armstrong DK, Bundy B, Wenzel L et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354(1), 34-43 (2006).
5. Kyrgiou M, Salanti G, Pavlidis N, Paraskevaidis E, Ioannidis JP: Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J. Natl Cancer Inst. 98(22), 1655-1663 (2006).
6. Advanced Ovarian Cancer Trialists' Group: Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Br. J. Cancer 78(11), 1479-1487 (1998).
7. Advanced Ovarian Cancer Trialists' Group: Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ 303(6807), 884-893 (1991).
8. Ovarian Cancer Meta-analysis Project: Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J. Clin. Oncol. 9(9), 1668-1674 (1991).
9. McGuire WP, Hoskins WJ, Brady MF et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334(1), 1-6 (1996).
10. Piccart MJ, Bertelsen K, James K et al.: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year result. J. Natl Cancer Inst. 92(9), 699-708 (2000).
11. Muggia FM, Braly PS, Brady MF et al.: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 18(1), 106-115 (2000).
12. Ozols RF, Bundy BN, Greer BE et al.: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer. J. Clin. Oncol. 21(17), 3194-3200 (2003).
13. du Bois A, Luck HJ, Meier W et al.: A randomized clinical trial of cisplatin/paclitaxel vs carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 95(17), 320-1329 (2003).
14. Neijt JP, Engelholm SA, Tuxen MK et al.: Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J. Clin. Oncol. 18(17), 3084-3092 (2000).
15. Morgan RJ Jr, Alvarez RD. Armstrong DK: Ovarian cancer. clinical practice guidelines in oncology. J. Natl Compr. Canc. Netw. 4(9), 912-939 (2006).
16. Cannistra SA: Cancer of the ovary. N. Engl. J. Med. 351(24), 2519-2529 (2004).
17. Dedrick RL, Myers CE, Bungay PM. DeVita VT Jr: Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treaty Rep. 62(1), 1-11 (1978).
18. Howell SB, Pfeifle CE, Wung WE et al.: Intraperitoneal cisplatin with systemic thiosulfate protection. Ann. Intern. Med. 97(6), 845-851 (1982).
19. Howell SB, Pfeifle CE, Wung WE, Olshen RA: Intraperitoneal cls-diamminedichloroplatinum with systemic thiosulfate protection. Cancer Res. 43(3), 1426-1431 (1983).
20. Casper ES, Kelsen DP. Alcock NW. Lewis JL Jr: IP cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat. Rep. 67(3), 235-238 (1983).
21. Lopez JA, Krikorian JG. Reich SD, Smyth RD, Lee FH, Issell BF: Clinical pharmacology of intraperitoneal cisplatin. Gynecol. Oncol. 20(1), 1-9 (1985).
22. Pretorius RG, Hacker NF, Berek JS et al.: Pharmacokinetics of IP cisplatin in refractory ovarian carcinoma. Cancer Treat. Rep. 67(12). 1085-1092 (1983).
23. Schneider JG: Intraperitoneal chemotherapy. Obstet. Gynecol. Clin. North Am. 21(1), 195-212 (1994).
24. Markman M, Rowinsky E, Hakes T et al.: Phase I trial of intraperitoneal Taxol: a Gynecologic Oncology Group study. J. Clin. Oncol. 10(9), 1485-1491 (1992).
25. Francis P. Rowinsky E, Schneider J, Hakes T, Hoskins W. Markman M: Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J. Clin. Oncol. 13(12), 2961-2967 (1995).
26. Kirmani S, Braly PS, McClay EF et al.: Comparison of intravenous versus Intraperitoneal chemotherapy for the initial treatment of ovarian cancer. Gynecol. Oncol. 54(3), 338-344 (1994).
27. Polyzos A, Tsavaris N, Kosmas C et al.: A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer. Oncology. 56(4), 291-296 (1999).
28. Gadducci A, Carnino F, Chiara S et al.: Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico, Nord-Ovest. Gynecol. Oncol. 76(2). 157-162 (2000).
29. Yen MS, Juang CM, Lai CR, Chao GC, Ng HT, Yuan CC: Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer. Int. J. Gynaecol. Obstet. 72(1), 55-60 (2001).
30. Piccart MJ, Floquet A, Scarfone G et al.: Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized Phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int. J. Gynecol. Cancer 13(Suppl. 2). 196-203 (2003).
31. McGuire WP: Intraperitoneal therapy for ovarian cancer: a sacrifice bunt. J. Clin. Oncol. 19(4), 921-923 (2001).
32. Makhija S, Leitao M, Sabbatini P et al.: Complications associated with intraperitoneal chemotherapy catheters. Gynecol. Oncol. 81(1), 77-81 (2001)
33. Alberts DS, Markman M, Armstrong D. Rothenberg ML, Muggia F. Howell SB: Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come! J. Clin. Oncol. 20(19), 3944-3946 (2002).
34. Fujiwara K, Markman M, Morgan M, Coleman RL: Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol. Oncol. 97(1), 10-15 (2005).
35. DeGregorio MW, Lum, BL, Holleran WM, Wilbur BJ, Sikic BI: Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the orthern California Oncology Group. Cancer Chemother. Pharmacol. 18(3), 235-238 (1986).
36. Elferink F, van der Vijgh WJF. Klein I, ten Bokkel Huinink WW, Dubbelman R, McVie JG: Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother. Pharmacol. 21(1). 57-60 (1988).
37. Hopkins MP, von Grueningen VE, Holds S, Weber B: The effect of intermittent-release intraperitoneal chemotherapy upon wound healing. Am. J. Obstet. Gynecol. 176(4), 819-823 (1997).
38. Armstrong DK, Fleming GF, Markman M, Bailey HH: A Phase I trial of Intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol. 103(2), 391-396 (2006).
39. Morgan RJ Jr, Doroshow JH, Synold T, et al.: Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin. Cancer Res. 9(16), 5896-5901 (2003).
40. Morgan RJ Jr, Synold T, Xi B et al.: Phase I trial of I.P. gemcitabine in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Clin. Cancer Res. 13(4), 1232-1237 (2007).